The MICROALBUMINURIA AS A POSSIBLE BIOMARKER IN EARLY DETECTION OF KIDNEY LESIONS IN PATIENTS WITH TYPE 2 DIABETES
The role of microalbuminuria in kidney lesions in the patients with type 2 diabetes
Abstract
Today, there is growing evidence supporting the association between renal failure and microalbumin (McA) concentration. The role of McA in the development of microcirculation damage in diabetic nephropathy (DN) has been proven. In our obsevational study were including 78 patients with type2 diabetes. The baseline level of McA showed to be significantly increased in patients with DN, and it was related to the severity of the renal disease. We were focusing on patients with a five-year-old diagnosis of diabetes mellitus type 2 (DM-2). After their a two-year follow-up, we found that microalbumin in urine increased afther 6 mounths and one year in some of patients. Microalbumin was determined using of turbidimetric method in the laboratory of the Institute of Medical and Experimental Biochemistry. For serum creatinine, we were using a standardized enzyme method. MDRD4 formula was the best for calculation of glomerular filtration rate. A statistical analysis of the data was performed with the statistical program IBM SPSS 26 for Windows. The results obtained regarding albumin in urine showed: mean 42.04 mg/L, extremely high CV, and were in negative correlation with GFR. Using a multivariate linear regression model, we proved the fact that the increased McA level in the urine significantly influenced the decline of GFR. In patients with a high risk of developing diabetic nephropathy, appropriate measures were taken in order to register and prevent the disease on time. The large variability could be due to differences in disease progression among individuals since microalbuminuria is a marker of early kidney damage, besides other promoters of progression.
Keywords: microalbuminuria, glomerular filtration rate, MDRD formula.
References
2.Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 2001;16(7):1382-1386. doi: 10.1093/ndt/16.7.1382.
3.Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6(10):2364-2373. doi: 10.2215/CJN.02180311.
4.Bilous R, Marshall S. Clinical aspects of nephropathy. In: Alberty K, Zimmet P, De Fronzo RA, editors. International Textbook of Diabetes Mellitus. 2nd ed. Chichester: Wiley & Sons; 1997. p. 97–108.
5.Zammit AR, Katz MJ, Derby C, Bitzer M, Lipton RB. Chronic kidney disease in non-diabetic older adults: associated roles of the metabolic syndrome, inflammation, and insulin resistance. PLoS ONE 2015;10(10):e0139369. doi: 10.1371/journal.pone.0139369.
6.Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb 2018;25(9):846-984. doi: 10.5551/jat.GL2017.
7.Tsai WC, Wu HY, Peng YS, Ko MJ, Wu MS, Hung KY, et al. Risk factors for development and progression of chronic kidney disease: a systematic review and exploratory meta-analysis. Medicine 2016;95(11):e3013. doi: 10.1097/MD.0000000000003013.
8.Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000;26(Suppl 4):8-14. PMID: 10922968.
9.Aderson S, Komers R. Pathogenesis of diabetic glomerulopathy: The role of glomerular hemodynamic factors. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. 5th ed. Boston: Kluwer Academic Publishers; 2000;281-294. https://doi.org/10.1007/978-1-4615-4499-9_24.
10.The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349(9068):1787-1792. PMID: 9269212.
11.Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004;47(6):1020-1028. doi: 10.1007/s00125-004-1413-8.
12.Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36(1):122-126. doi: 10.1161/01.hyp.36.1.122.
13.Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32(4):219-226. doi: 10.1007/BF00285287.
14.Dragovic T, Mijuskovic Z, Karajovic J, Andjelkovic Z. Effect of AT1 receptor blockers on plasma lipid profiles in Type 1 diabetic patients with incipient diabetic nephropathy. Yugoslav Med Biohem 2005; 24(1): 21-26. doi: 10.2298/JMH0501021D.
15.Fenton JJ, Von Korff M, Lin EH, Ciechanowski P, Young BA. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006;4(1):32-39. doi: 10.1370/afm.421.
16.Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Association of metabolic syndrome and chronic kidney disease. Obes Rev. 2024 Jan;25(1):e13649. doi: 10.1111/obr.13649. Epub 2023 Oct 2. PMID: 37783465.
